Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)

The summary for the Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for Exploratory Centers for Interdisciplinary Research in Benign Urology (P20). A major goal of this program is to build interdisciplinary research teams. The program seeks innovative, high-riskhigh-reward Research Projects that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders bringing together investigators with complementary expertise. Studies involving human subjects or tissues and small, innovative, pilot and feasibility clinical studies are encouraged. The following expertise must be included in the proposed Research Project: 1) researchers new to the investigation of benign genitourinary diseases or disorders and 2) clinical urology expertise. Additional expertise may also be included, as needed. In addition to the scientific Research Project, each Exploratory Center must include an Administrative Core with an Educational Enrichment Program. As part of the NIDDK's efforts to expand and enhance benign urology research and the base of urologic researchers, the Exploratory Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.

Federal Grant Title:	Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-19-033
Type of Funding:	Grant
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 30th, 2020
Original Application Deadline:	June 30th, 2020
Posted Date:	November 12th, 2019
Creation Date:	November 12th, 2019
Archive Date:	July 30th, 2020
Total Program Funding:	$1,000,000
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:	3
Cost Sharing or Matching:	No
Last Updated:	April 13th, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-033.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...; • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...; • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...; • Diabetes Research Centers (P30 Clinical Trial Optional); • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...